Copy to clipboard 
Globus Medical entered into a definitive agreement to acquire all shares of Nevro for $5.85/share in an all-cash transaction. The transaction represents a total equity value of ~$250 million. The deal is slated to close in late 2Q25.
The purchase brings the Nevro1 SI Joint Fusion System, a posterior integrated transfixation cage designed to offer enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. Study data reported in late 2024 indicated that Nevro1 performed equivalently in osteopenic bone when compared to a lateral triangular rod system in healthy bone.
At the close of 2023, Nevro acquired Vyrsa Technologies and its portfolio of FDA-cleared sacroiliac joint fusion devices.
Nevro also markets the HFX spinal cord stimulation platform for the treatment of chronic pain in the leg or back, as well as diabetic neuropathy.
The move has some investors scratching their heads, but it is a relatively cheap, low-risk move that could have some upside for Globus.
The company’s existing SI joint offering has room to grow. Additionally, on the competitive front, Stryker opted to keep its interventional spine products and said it was one of its fastest-growing segments with the addition of Vertos Medical. Globus may be able to find some synergies within its new interventional products and its existing imaging portfolio, as well.
“This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions. We believe our size and operational capabilities will accelerate market penetration of Nevro’s technology and bring much needed and clinically superior relief to patients suffering from chronic pain,” said Dan Scavilla, President and CEO of Globus Medical. “In addition, our scale and operational discipline will allow us to optimize Nevro’s financial performance to drive enhanced profitability and create long-term value moving ahead.”
Source: Globus Medical, Inc.
Globus Medical entered into a definitive agreement to acquire all shares of Nevro for $5.85/share in an all-cash transaction. The transaction represents a total equity value of ~$250 million. The deal is slated to close in late 2Q25.
The purchase brings the Nevro1 SI Joint Fusion System, a posterior integrated transfixation cage designed to...
Globus Medical entered into a definitive agreement to acquire all shares of Nevro for $5.85/share in an all-cash transaction. The transaction represents a total equity value of ~$250 million. The deal is slated to close in late 2Q25.
The purchase brings the Nevro1 SI Joint Fusion System, a posterior integrated transfixation cage designed to offer enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. Study data reported in late 2024 indicated that Nevro1 performed equivalently in osteopenic bone when compared to a lateral triangular rod system in healthy bone.
At the close of 2023, Nevro acquired Vyrsa Technologies and its portfolio of FDA-cleared sacroiliac joint fusion devices.
Nevro also markets the HFX spinal cord stimulation platform for the treatment of chronic pain in the leg or back, as well as diabetic neuropathy.
The move has some investors scratching their heads, but it is a relatively cheap, low-risk move that could have some upside for Globus.
The company’s existing SI joint offering has room to grow. Additionally, on the competitive front, Stryker opted to keep its interventional spine products and said it was one of its fastest-growing segments with the addition of Vertos Medical. Globus may be able to find some synergies within its new interventional products and its existing imaging portfolio, as well.
“This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world by enabling us to expand into new markets for future growth, while gaining access to world-class, differentiated technologies that can provide significant benefit in neuromodulation, enabling technologies, and future implant solutions. We believe our size and operational capabilities will accelerate market penetration of Nevro’s technology and bring much needed and clinically superior relief to patients suffering from chronic pain,” said Dan Scavilla, President and CEO of Globus Medical. “In addition, our scale and operational discipline will allow us to optimize Nevro’s financial performance to drive enhanced profitability and create long-term value moving ahead.”
Source: Globus Medical, Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
